Annexin Pharmaceuticals AB Stock
Stocks
ANNX
SE0025159387
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.15 SEK | +1.25% |
|
-1.22% | -38.64% |
| 06-15 | Five stocks hit new 52-week lows on the Stockholm Stock Exchange today | FW |
| 06-10 | Calendar Wednesday June 10 | FW |
| Market Cap | 85.77M 8.95M 7.81M 7.23M 6.77M 12.69M 845M 12.77M 33.24M 416M 33.61M 32.89M 1.44B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 85.77M 8.95M 7.81M 7.23M 6.77M 12.69M 845M 12.77M 33.24M 416M 33.61M 32.89M 1.44B | EV / Sales 2026 * |
1.13x | EV / Sales 2027 * | - |
| Free-Float |
23.86% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +1.25% | ||
| 1 week | -1.22% | ||
| Current month | -10.33% | ||
| 1 month | -12.59% | ||
| 3 months | -16.21% | ||
| 6 months | -36.39% | ||
| Current year | -38.64% |
| 1 week | 11.05 |  | 12.3 |
| 1 month | 11.05 | | 15.05 |
| Current year | 11.05 | | 23.6 |
| 1 year | 11.05 | | 35.8 |
| 3 years | 11.05 | | 109 |
| 5 years | 11.05 | | 225 |
| 10 years | 11.05 | | 1,320 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2018-12-31 | |
Anna Frostegård
CTO | Chief Tech/Sci/R&D Officer | 53 | 2015-12-31 |
| Director of Finance/CFO | 55 | 2023-04-10 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 50 | 2016-12-31 | |
| Director/Board Member | 73 | - | |
Jan Nilsson
CHM | Chairman | 77 | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.25% | -1.22% | -53.98% | -87.91% | 8.95M | |
| +1.44% | -1.25% | +63.52% | +114.88% | 55.19B | |
| +4.60% | +3.02% | +58.20% | +47.16% | 45.75B | |
| -1.44% | +0.39% | -12.94% | -19.24% | 22.98B | |
| -2.69% | -2.10% | -3.68% | +379.00% | 20.76B | |
| +3.22% | -0.84% | +27.88% | -34.00% | 16.26B | |
| +0.58% | +1.08% | +16.73% | -38.06% | 15.42B | |
| -1.01% | -2.30% | +27.42% | +171.92% | 13.05B | |
| +4.95% | +11.70% | +123.63% | +252.19% | 12.45B | |
| +3.07% | +0.14% | +29.37% | - | 12.37B | |
| Average | +1.40% | +1.46% | +27.62% | +87.33% | 21.42B | |
| Weighted average by Cap. | +1.63% | +1.47% | +40.91% | +99.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 75.6M 7.89M 6.88M 6.37M 5.97M 11.19M 745M 11.26M 29.3M 367M 29.62M 28.99M 1.27B | - |
| Net income | 19.6M 2.05M 1.78M 1.65M 1.55M 2.9M 193M 2.92M 7.6M 95.02M 7.68M 7.52M 330M | -58M -6.05M -5.28M -4.89M -4.58M -8.58M -571M -8.64M -22.48M -281M -22.73M -22.24M -976M |
| Net Debt | - | - |
Employees
4
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-18 | 12.15 kr | +1.25% | 1,220 |
| 26-06-17 | 12.00 kr | -1.64% | 12,598 |
| 26-06-16 | 12.20 kr | 0.00% | 6,797 |
| 26-06-15 | 12.20 kr | -0.81% | 17,449 |
| 26-06-12 | 12.30 kr | -4.28% | 16,865 |
Net sales - Rate of surprise
- Stock Market
- Stocks
- ANNX Stock
Select your edition
All financial news and data tailored to specific country editions
